Overview

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Status:
Terminated

Trial end date:
2019-04-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

The Netherlands Cancer Institute

Collaborator:

Dutch Society of Physicians for Pulmonology and Tuberculosis

Treatments:

Docetaxel
Erlotinib Hydrochloride